Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.49 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15550053 | 0.82 | HPGD (0.52) | NPC1RAB9ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL4043511 | 0.82 | HPGD (0.64) | NPC1RAB9ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL29953310 | 0.82 | HPGD (0.52) | NPC1RAB9ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL178430 | 0.81 | TAS1R3 (0.66) | NPC1RAB9ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL15341542 | 0.80 | NPC1 (0.54) | NPC1RAB9ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL457266 | 0.79 | NEU3 (0.39) | HPGDSMN1; SMN2 | |
| SCHEMBL29955977 | 0.79 | HPGD (0.55) | NPC1RAB9ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL15940756 | 0.79 | HPGD (0.55) | NPC1RAB9ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL455691 | 0.78 | RAB9A (0.53) | NPC1RAB9ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3233932 | 0.78 | NPC1 (0.53) | NPC1RAB9ATAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305912-A1 | PROCESS FOR THE PREPARATION OF 3-PHENYL/HETEROARYL-6-PHENOXY-8-ALKYLAMINO-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-26 | — | — | US | claimed |
| EP-3189055-A1 | A PROCESS FOR THE PREPARATION OF 3-PHENYL/HETEROARYL-6-PHENOXY-8-ALKYLAMINO-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2017-07-12 | — | — | EP | claimed |
| WO-2016034507-A1 | A PROCESS FOR THE PREPARATION OF 3-PHENYL/HETEROARYL-6-PHENOXY-8-ALKYLAMINO-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-10 | — | — | WO | claimed |
| US-20170305912-A1 | PROCESS FOR THE PREPARATION OF 3-PHENYL/HETEROARYL-6-PHENOXY-8-ALKYLAMINO-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-26 | — | — | US | disclosed |
| US-20170305912-A1 | PROCESS FOR THE PREPARATION OF 3-PHENYL/HETEROARYL-6-PHENOXY-8-ALKYLAMINO-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-26 | — | — | US | disclosed |
| US-20170305912-A1 | PROCESS FOR THE PREPARATION OF 3-PHENYL/HETEROARYL-6-PHENOXY-8-ALKYLAMINO-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-26 | — | — | US | disclosed |
| EP-2961752-B1 | SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Pharma AG (DE) | 2017-09-13 | — | — | EP | disclosed |
| EP-2961752-B1 | SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Pharma AG (DE) | 2017-09-13 | — | — | EP | disclosed |
| EP-3189055-A1 | A PROCESS FOR THE PREPARATION OF 3-PHENYL/HETEROARYL-6-PHENOXY-8-ALKYLAMINO-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2017-07-12 | — | — | EP | disclosed |
| US-9512130-B2 | Substituted imidazopyridazines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-06 | — | — | US | disclosed |
| US-9512130-B2 | Substituted imidazopyridazines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-06 | — | — | US | disclosed |
| US-20130303532-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| EP-2651948-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | Bayer Intellectual Property GmbH (DE) | 2013-10-23 | — | — | EP | disclosed |
| EP-2614063-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Intellectual Property GmbH (DE) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012136531-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012136531-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012130905-A1 | SUBSTITUTED BENZIMIDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012130905-A1 | SUBSTITUTED BENZIMIDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012080229-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012032031-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303532-A1 | IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS | TK1, CDKL1, CDK1 | NPC1 2059/4885RAB9A 3903/4885TAS1R3 2536/4885 |
| US-20170305912-A1 | PROCESS FOR THE PREPARATION OF 3-PHENYL/HETEROARYL-6-PHENOXY-8-ALKYLAMINO-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | TTBK1, TTK, TTBK2 | NPC1 2377/4885RAB9A 2878/4885TAS1R3 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.